U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on drug pricing policy.

E&C full committee chair Frank Pallone (D-N.J.) and Oversight and Investigations subcommittee chair Diana DeGette (D-Colo.) sent the letters to insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi last week. Pallone and DeGette sent the three companies letters in January 2019 requesting information on the root causes of the rising cost of insulin. DeGette’s subcommittee health a hearing on insulin affordability three months later.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on drug pricing policy.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer